Cost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck

Justin Yeh, William Black, Achuta K. Guddati

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Cost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Medicine & Life Sciences